Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI
Status:
Withdrawn
Trial end date:
2020-01-13
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine in patients receiving intravenous (IV)
antibiotic(s), if giving oral vancomycin therapy will prevent C. difficile-associated
infection (commonly called CDI). Oral vancomycin is an antibiotic that is commonly used to
treat CDI. The investigators want to study if using this drug can prevent the development of
CDI while you are in the hospital receiving IV antibiotics. The key risk factors for
developing CDI are age and IV antibiotic therapy. CDI is an infection in your colon caused by
an organism called Clostridium difficile (or C. diff for short) that causes diarrhea. Up to
12% of hospital-acquired infections have been reported to be CDI. It can lead to longer
hospital stays and more costs associated with the hospital stay.